meibomian gland dysfunction
Conditions
Interventions
Group A:IPL flashes are applied on the forehead, the temporal area and 3 millimeters below the lower eyelid.
Group B:IPL flashes are applied on the forehead, the temporal area and 10 millimeters below the lower eyelid.
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged at least 18 years; (2) Fitzpatrick skin type 1-4; (3) Standard dry eye questionnaire (SPEED) score = 6; (4) Meibomian gland function score = 12 ; (5) Tear film break-up time (TBUT) = 10 seconds*; (6) Corneal fluorescein staining score = 1; (7) The subjects must sign an informed consent form, willing to comply with the treatment and follow-up schedule, and participate voluntarily in this study. *Note: If TBUT =5 seconds, do not considerate criterion 6.
Exclusion criteria
Exclusion criteria: (1) Pregnancy and nursing; (2) Contact lens wearer; (3) Acute ocular inflammation or infection; (4) There is obvious scar or keratinization on the eyelid; (5) received eye surgery or eyelid surgery within 6 months prior to enrollment; (6) Neuroparalysis occurred in the treatment area within 6 months before enrollment; (7) Tear plug is being used; (8) precancerous lesions in the treatment area, skin cancer or pigmentation; (9) received LASIK surgery within 6 months prior to enrollment; (10) The treated area suffers from diseases that may be stimulated by light waves of 560 nm to 1200 nm, such as herpes simplex types 1 and 2, systemic lupus erythematosus and porphyria; (11) taking photosensitizers, such as isotretinoin, tetracycline or St. John's wort; (12) Eye drops for dry eye within 48 hours before enrollment (except for artificial tears); (13) The history of head and neck radiotherapy within 1 year before enrollment, or radiotherapy within 8 weeks after intensive pulsed light therapy is expected; (14) Chemotherapy history within the first 8 weeks of enrollment, or chemotherapy within 8 weeks after intense pulsed light therapy is expected; (15) history of migraine or epilepsy; (16) A face intense pulsed light treatment was performed within one year before enrollment. (17) excessive exposure in the first 4 weeks before enrollment; (18) Other conditions judged by the researcher as unsuitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| meibomian gland assessment;levels of inflammatory factors in tears; | — |
Secondary
| Measure | Time frame |
|---|---|
| tear break-up time;standard patient evaluation of eye dryness2;corneal fluorescein staining;Infrared imaging of meibomian gland;standard vision;intraocular pressure;observation of palpebral margin and anterior segment;confocal microscopy of meibomian glands;levels of inflammatory factors in blood; | — |
Countries
China
Contacts
Public ContactXiaoming Yan
Peking University First Hospital
Outcome results
None listed